Navigation Links
iCardiac Expands Sales and Marketing Team
Date:8/6/2009

Adds Industry Veteran with Over Two Decades of Cardiovascular Core Lab Experience

Rochester, NY (PRWEB) August 6, 2009 -- iCardiac Technologies, Inc., a leader in advanced cardiac safety ECG services and automated QT analysis, announced that it has expanded its sales and marketing team by hiring Susan Boyle as Senior Director of Business Development. Ms. Boyle has over two decades of experience in operations and business development in the clinical research industry, specializing in centralized cardiovascular diagnostic services at a number of leading core laboratories.

"We are excited to welcome Susan to the iCardiac team," said Sasha Latypova, Executive Vice President. "Susan's deep client relationships and long history of successfully partnering with clinical pharmacology units will allow iCardiac to better serve its rapidly broadening set of customers and channel relationships."

"I am proud to join iCardiac at this exciting transformation point in the cardiac core laboratory industry," said Ms. Boyle. "iCardiac has driven a dramatic shift in the industry by establishing the company as both a leader in Highly Automated QT evaluation as well as advanced techniques for avoiding false positives and negatives in cardiac safety studies."

About iCardiac Technologies
iCardiac Technologies, Inc. is a technologically differentiated cardiac core lab providing expert scientific consultation, end-to-end project management, statistical analysis and the industry's most sophisticated FDA-accepted cardiac safety assessment methodologies. iCardiac's analysis service provides drug developers with more precise and cost-effective methods for ECG/QT interval measurements, including Highly Automated QT, which has been validated by pharmaceutical companies and is now used in regulatory submissions as equivalent to the manual evaluation of ECGs in Thorough QT studies. In addition, iCardiac provides Beyond QT, a suite of advanced ECG-based cardiac safety markers that have been accepted and used as secondary end-points by the regulators, and deliver a more accurate assessment of the cardiac safety profile of drugs in development. iCardiac's COMPAS technology has been used for over a decade in cardiac clinical trials conducted for and by leading large and medium sized pharmaceutical, biotechnology, and medical device companies. For more information, visit: www.icardiac.com.

# # #

Read the full story at http://www.prweb.com/releases/icardiac/business/prweb2715644.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. iCardiac Reports Significant Revenue Growth and Profitability
2. iCardiac Applies Advanced Cardiac Safety Biomarkers in Clinical Study for Top Pharmaceutical Company
3. iCardiac Selected for Multiple Cardiac Safety Studies
4. iCardiac Selected by Top 10 Pharmaceutical Company
5. iCardiac Processes Volume of Data Equivalent to One Thousand Traditional Thorough QT Studies
6. ATS Medical Expands Open Pivot Heart Valve Offerings
7. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
8. BioLife Solutions Expands Scientific Advisory Board
9. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
10. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
11. Pharsight Expands Strategic Consulting Services Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... New York, NY (PRWEB) , ... October 12, ... ... York Academy of Sciences today announced the three Winners and six Finalists of ... Awards are given annually by the Blavatnik Family Foundation and administered by the ...
(Date:10/12/2017)... ... October 12, 2017 , ... AMRI, ... and biotechnology industries to improve patient outcomes and quality of life, will now ... testing are being attributed to new regulatory requirements for all new drug products, ...
(Date:10/11/2017)... ... October 11, 2017 , ... Personal eye wash is a basic first aid supply for any ... So which eye do you rinse first if a dangerous substance enters both eyes? It’s ... Wash with its unique dual eye piece. , “Whether its dirt and debris, or ...
(Date:10/11/2017)... LAGUNA HILLS, Calif. , Oct. 11, 2017 ... London (ICR) and University of ... prognostic tool to risk-stratify patients with multiple myeloma (MM), in ... nine . The University of Leeds ... by Myeloma UK, and ICR will perform the testing services ...
Breaking Biology Technology:
(Date:5/6/2017)... SINGAPORE , May 5, 2017 ... has just announced a new breakthrough in biometric ... that exploits quantum mechanical properties to perform ... new smart semiconductor material created by Ram Group ... across finance, entertainment, transportation, supply chains and security. ...
(Date:4/13/2017)... 13, 2017 UBM,s Advanced Design and Manufacturing ... feature emerging and evolving technology through its 3D Printing ... run alongside the expo portion of the event and ... demonstrations focused on trending topics within 3D printing and ... manufacturing event will take place June 13-15, 2017 at the ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
Breaking Biology News(10 mins):